Dynamic 13N-ammonia PET is used to assess ammonia metabolism in brain, liver and muscle based on kinetic modeling of metabolic pathways, using arterial blood 13N-ammonia as input function. Rosenspire et al. (1990) introduced a solid phase extraction procedure for fractionation of 13N-content in blood into 13N-ammonia, 13N-urea, 13N-glutamine and 13N-glutamate. Due to a radioactive half-life for 13N of 10 min, the procedure is not suitable for blood samples taken beyond 5–7 min after tracer injection. By modifying Rosenspire’s method, we established a method enabling analysis of up to 10 blood samples in the course of 30 min. The modified procedure was validated by HPLC and by 30-min reproducibility studies in humans examined by duplicate 13N-ammonia injections with a 60-min interval. Blood data from a 13N-ammonia brain PET study (from Keiding et al. 2006) showed: (1) time courses of 13N-ammonia fractions could be described adequately by double exponential functions; (2) metabolic conversion of 13N-ammonia to 13N-metabolites were in the order: healthy subjects > cirrhotic patients without HE > cirrhotic patients with HE; (3) kinetics of initial tracer distribution in tissue can be assessed by using total 13N-concentration in blood as input function, whereas assessment of metabolic processes requires 13N-ammonia measurements.
Hinweise
In this paper, the term ammonia refers to the sum of unionized NH3 and ionized NH4+
Introduction
Hepatic encephalopathy (HE) is a severe neurological condition arising secondary to liver failure. Hyperammonemia is considered a major causative factor because most patients with HE have elevated blood concentrations of ammonia, which in high concentrations is neurotoxic (Cooper and Plum 1987; Jones and Basile 1998; Cooper 2001; Butterworth 2002: Johansen et al. 2007; Iversen et al. 2009). Dynamic 13N-ammonia PET has been used in humans to assess ammonia metabolism in brain (Lockwood et al. 1979, 1984, 1991; Ahl et al. 2004; Weissenborn et al. 2004; Keiding et al. 2006; Sørensen and Keiding 2007a; Sørensen et al. 2009; Berding et al. 2009), liver (Keiding et al. 2001, 2005; Sørensen and Keiding 2007b) and muscle (Nishiguchi et al. 2003). The PET procedure encompasses intravenous injection of 13N-ammonia tracer followed by dynamic measurements of radioactivity concentrations in arterial blood (samples) and tissue (PET camera). Data are analyzed by fitting kinetic models of the metabolic pathways to the time courses of the tissue radioactivity concentrations, using the time course of radioactivity concentrations in blood as input function. However, appearance of 13N-urea, 13N-glutamine and other 13N-labelled amino acids in blood (Cooper et al. 1979; Lockwood et al. 1979; Nieves et al. 1986; Rosenspire et al. 1990; Keiding et al. 2006) complicates the kinetic analysis. Consequently the analysis of dynamic 13N-ammonia PET studies is sometimes limited to assessment of distribution and transport processes across the plasma membrane during the very first minutes after tracer injection, using total 13N-radioactivity concentration in blood as input function (Ahl et al. 2004). In agreement with this, we showed that formation of 13N-metabolites can be ignored for the assessment of the initial distribution of tracer (Sørensen and Keiding 2006). However, calculation of parameters of steady-state metabolic processes requires the use of metabolite-corrected input functions, i.e. 13N-ammonia concentrations (Keiding et al. 2006, Sørensen and Keiding 2006; Bass et al. 2009).
Various attempts have been made to fractionate un-metabolized 13N-ammonia and 13N-labelled metabolites in blood (Cooper et al. 1979; Lockwood et al. 1979; Nieves et al. 1986; Rosenspire et al. 1990). The most robust method was published by Rosenspire et al. (1990) who introduced a sequential solid phase extraction procedure which combines the use of cation and anion exchange resins, allowing for fractionation of the 13N-content in blood into 13N-acidic amino acids, 13N-ammonia, 13N-neutral amino acids, and 13N-urea. However, only results from blood samples taken up to 5 min after injection of 13N-ammonia in healthy human subjects were published (Rosenspire et al. 1990). Due to the radioactive half-life of 13N-nitrogen of 10 min the method is not suitable for blood samples taken beyond 5–7 min after injection of the 13N-ammonia tracer. By modifying Rosenspire’s method, we established a method which enables us to analyze up to 10 blood samples in the course of a 30-min dynamic human 13N-ammonia PET study (Keiding et al. 2006). In the present study we describe our technical modifications of Rosenspire’s method and give detailed reports of the 13N-metabolite measurements in Keiding et al. (2006), including validation by means of radio-HPLC measurements and studies of reproducibility in 30-min studies of human subjects who were given two successive 13N-ammonia injections.
Anzeige
Material and methods
Human subjects
The method was used to determine 13N-metabolites in blood samples in a brain PET study of 5 healthy subjects, 8 cirrhotic patients with type C HE, and 7 cirrhotic patients with neither overt, nor minimal HE (Keiding et al. (2006) and here we give a detailed report of the technical procedure and the 13N-metabolite measurements. Data from another five patients with compensated liver cirrhosis who were given two injections of 13N-ammonia at a 60-min interval are also included.
13N-ammonia was produced at the radiochemistry facility of the PET Centre, Aarhus University Hospital, with a radiochemical purity >98% and a specific radioactivity of 30–40 GBq/µmol. 500 MBq 13N-ammonia was injected intravenously over 15 s, and arterial blood samples were collected via a small catheter placed in a radial artery (Artflon Becton Dickinson, Swindon, UK) in heparinized 1.5 ml Eppendorf tubes after 1, 2, 3, 5, 7, 10, 15, 20, 25, and 30 min.
All studies were approved by the Ethics Committee of Aarhus County, and informed consent was obtained from each subject. No complications to the procedure were observed.
Preparation of solid phase extraction columns
Three columns for the sequential solid phase extraction procedure were prepared at the PET Centre. Plungers from 1 ml Tuberculin syringes (Codan Medical Aps, Rødby, Denmark) were removed, and quartz wool was put into the syringes to fix exchange resins in the syringes. The resins were conditioned immediately before each study. All chemicals for conditioning the ion exchange resins were purchased from Sigma-Aldrich Denmark, Vallensbæk Strand, Denmark. Column 1: Dowex 1X8–50 anion exchange resin, 20–50 mesh, chloride form was converted to the acetate form by flushing the resin with at least 10 volumes of 0.75 M sodium acetate trihydrate solution. 0.5–0.6 ml of this anion exchange resin in acetate form was manually filled in the 1 ml syringe. Column 2: AG 50 W-X8 resin hydrogen form 100–200 mesh (Bio-Rad Laboratories, Hercules, CA) was converted to tris(hydroxymethyl)aminomethane (TRIS) form by flushing the resin with at least 10 volumes of a solution prepared from 0.8 M solution of TRIS acetate (freshly prepared from equal molar amounts of TRIS and glacial acetic acid). 250–350 µL of this resin were manually filled in the 1 ml syringe. Column 3: AG 50 W-X8 resin hydrogen form 100–200 mesh (Bio-Rad Laboratories, Hercules, CA) was flushed with at least 10 volumes of Millipore water. 250–350 µL of this resin were manually filled in 1 ml syringes.
Anzeige
The employed Bio-Rad AG 50 W-X8 resin is chemically equivalent to the originally used Dowex 50(H+) resin by Rosenspire et al. (1990).
The original method by Rosenspire et al. (1990) comprised elution of resin-bound radioactivity with 2 M potassium chloride solution for radioactivity measurements in a well counter. In our adaptation, the syringes, containing the resins and trapped 13N-metabolites, were placed directly in the well counter.
Solid phase extraction procedure
A volume of 0.5 ml whole-blood was added to 0.5 ml of a 10 wt% solution of sulfosalicylic acid. After vigorous shaking, the samples were centrifuged for 2 min at 13,000 rpm to precipitate proteins. For solid phase extraction procedures, Alltech Visiprep® manifolds were employed. As illustrated in Fig. 1, the supernatant from the worked-up blood sample was transferred on to Column 1 containing the acetate-conditioned resin, followed by 5–10 s suction through the resin. The resin was washed with 4 ml of Millipore water. The column with resin-bound radioactivity was transferred into a counting tube and radioactivity was measured in a well counter (13N-containing acidic amino acids; mainly 13N-glutamate). The mixed eluate and Milipore water was then sucked through Column 2, containing TRIS-conditioned resin. The resin was washed with 2 × 3.5 ml Millipore water, and resin-bound radioactivity (13N-ammonia) was measured in a well counter. The mixed eluate and Milipore water was sucked through Column 3, containing resin in hydrogen form. This resin was washed with 3 × 3.5 ml water and the resin-bound radioactivity counted in a well counter (13N-labeled neutral amino acids; mainly 13N-glutamine). According to Rosenspire et al. (1990), the radioactivity in the final washing solution is attributed to 13N-urea. The solution (final eluate+Milipore water) was collected in a pre-weighed plastic beaker and 5 ml of the solution was counted in a well counter. The pre-weighed plastic beaker was weighed again, and the amount of radioactivity in the 5 ml solution was related to the entire final volume.
Fig. 1
Diagram of sequential solid phase fraction extraction procedure for determination of 13N-metabolites
×
To ensure a high through-put of samples, we used 2 Visiprep manifolds simultaneously.
Counting statistics
Count rates were generally lower for blood samples taken at late time points than for blood samples taken earlier because of the radioactive half-life of 10 min resulting in less accurate counting statistics (Table 1). The measurement accuracy was slightly better for the first two fractions, i.e. for 13N-glutamate and 13N-ammonia than for the 13N-glutamine and 13N-urea fractions, probably due to adsorption of 13N-substances to the plastic tubes during elution and transfer of the liquids (Fig. 1 and Table 1). Furthermore, the relative large measurement uncertainty for 13N-urea may be explained by the poor counting statistics due to dilution of 0.5 ml blood to approximately 20 ml during the procedure and counting of only 5 ml of this solution in the well counter.
Table 1
Reproducibility of the modified sequential solid phase extraction procedure for measurement of 13N-labelled metabolites in blood
13N-glutamate
13N-ammonia
13N-glutamine
13N-urea
Coefficient of variation (%)
1.5 (0.1–7)
7.7 (0–28.9)
11.2 (0.1–42.5)
17.9 (0–57.3)
Data are shown as mean and range of coefficients of variation between two measurements of 13N-fractions in blood samples taken 1–30 min after intravenous administration of 500 MBq 13N-ammonia to 5 cirrhotic patients without HE (Fig. 2). For each metabolite the lowest value is from the 1-min time point and the highest value from the 30-min time point
Rosenspire et al. (1990) also proposed a simplified solid phase extraction procedure, using separation into only two fractions, 13N-ammonia and 13N-metabolites. However, in our hands this procedure overestimated the 13N-ammonia fraction because of insufficient removal of especially 13N-urea.
Radio-HPLC
Radio-HPLC was used for validation of the solid phase extraction procedure. The radio-HPLC analysis of 13N-ammonia and 13N-metabolites was adopted from Nieves et al. (1986), using a cation exchange HPLC column with two different phosphate buffers. The time required for analyzing one blood sample was 25–30 min. Because of this and the physical half-life of 13N of 10 min, we restricted the use of the radio-HPLC analysis to blood samples taken 5 and 15 min after tracer injection (from Keiding et al. 2006).
When compared to the radio-HPLC results, the solid phase extraction procedure yielded valid estimates of the individual 13N-metabolite fractions.
Anzeige
Results and discussion
Reproducibility
The reproducibility study showed no significant difference between the two time courses of the 13N-ammonia fractions for any of the 5 subjects (Fig. 2) or any of the other 13N-fractions. Coefficients of variation for each of the four fractions indicate good reproducibility being best in the first minutes after the 13N-ammonia tracer injection due to better counting statistics (Table 1). Overall, measurement accuracy was fine for the present purpose.
Fig. 2
Reproducibility study. Time courses of the 13N-ammonia fractions in arterial blood in 5 cirrhotic patients without HE, each studied by two successive 13N-ammonia injections with a 60-min interval. Data points from the two injections in a patient are shown by similar symbols, being open and closed, respectively, and points from each injection are connected by lines with the same type of line
×
Time course of 13N-metabolite fractions
The time courses of the 13N-ammonia fractions after tracer injection in the three groups of human subjects in Keiding et al. (2006) are shown in Fig. 3 and typical examples of the time course of the 13N-metabolite fractions in a cirrhotic patient with HE and a healthy subject are shown in Fig. 4 (from Keiding et al. 2006). 13N-urea and 13N-glutamine appeared at a slower rate in the cirrhotic patients than in the healthy subjects, as illustrated in Fig. 4. Both the 13N-ammonia fractions and the 13N-metabolite fractions had an initial time delay of a little less than 1 min. This can be ascribed to combined effects of blood circulation time and time delay for formation of 13N-metabolites. The 30-min time courses of the 13N-ammonia fractions were described adequately by double exponential curves with an initial time delay (Fig. 3 and Table 2). The decreasing 13N-ammonia fraction was divided into of an initial fast component (A and α) and a final slow component ((100%–A) and β) (Table 2). We ascribe the fast component as the result of metabolic conversion of the injected 13N-ammonia into 13N-metabolites, see also Fig. 4.
Fig. 3
Time course of fractions of 13N-ammonia in arterial blood in three groups of subjects as indicated (from Keiding et al. 2006). Curves are double exponential fits (see Table 2)
Fig. 4
Examples of 13N-metabolite fractions in arterial blood in a cirrhotic patient with HE (closed symbols) and a healthy subject (open symbols)
Table 2
Parameters from fitting double exponential equations to the time courses of 13N-ammonia fractions in arterial blood (from Keiding et al. 2006) following iv 500 MBq 13N-ammonia tracer injection: 13N-ammonia fraction = \( A{e^{ - \alpha \left( {t - td} \right)}} + \left( {100 - A} \right){e^{ - \beta \left( {t - td} \right)}} \). The 13N-ammonia fraction is 100% between t = 0 and t=td
Parametera
Healthy subjects
Cirrhotic patients without HE
Cirrhotic patients with HE
td (min)
0.95
0.99
0.91
A (%)
90
77
78
α (min-1)
0.35
0.35
0.22
β (min-1)
0.4 10-2
2.2 10-2
0.4 10-2
aDouble exponential equation: 13N-ammonia fraction (%); t is time after tracer injection (min); td is time delay between tracer injection and appearance of 13N-metabolites in blood (min); A and (100%–A) are the coefficients (%); α and β are exponents of the fast and slow components, respectively (min-1)
×
×
The metabolic conversion of 13N-ammonia comprised a larger part in the group of healthy subjects (A = 90%) than in the two groups of patients with cirrhosis (77% and 78%, respectively) and it was slower in the group of cirrhotic patients with HE (α, 0.22 min-1) than in the two other groups of subjects (α, 0.35 min-1 in both groups) (Table 2). Overall the data thus indicate that the metabolic conversion of ammonia took place in the order: healthy subjects > cirrhotic patients without HE > cirrhotic patients with HE.
It is noticeably that the subsequent slow component does not approximate zero within the present 30-min study period. It is influenced not only by continued metabolic conversion of 13N-ammonia, but also by formation of 13N-ammonia from breakdown of 13N-glutamine in muscle tissue (Duda and Handler 1958; Mobley and Hausinger 1989; Cooper 2001; Nishiguchi et al. 2003; Sørensen and Keiding 2006), breakdown of 13N-urea by ureases in the intestines (Prior and Visek 1972; Hansen and Vilstrup 1985; Mobley and Hausinger 1989) and unequal volumes of distribution of the formed metabolites (Berl et al. 1962).
Anzeige
In our brain PET study we found that separate accounting for blood 13N metabolites improved the goodness of the kinetic fitting as evaluated by residuals of the fits when compared with a model ignoring the time courses of the metabolites (Keiding et al. 2006).
Time courses of 13N-ammonia concentrations and body clearance of 13N-ammonia
The time course of the 13N-ammonia concentration in blood was calculated from the measured total 13N-concentration (Fig. 5) and the 13N-ammonia fractions (Fig. 4 and Table 2) in each subject. The time course of the blood concentration of 13N-ammonia depends on 13N-metabolite formation and distribution of 13N-ammonia and 13N-metabolites. In general, blood concentration of 13N-ammonia decreased faster and to a lower level within the present experimental period the healthy subjects than in the patients with cirrhosis (Fig. 5 shows an example). We therefore tested the hypothesis that whole-body clearance of ammonia was decreased in the patients with cirrhosis (Sørensen and Keiding 2006). All subjects received the same dose of 13N-ammonia tracer, and we therefore used the areas-under-the-curve of the 13N-ammonia concentrations as approximate “inverse” estimates of whole-body clearance of ammonia (Fig. 6). It is seen that AUC was approximately the same in cirrhotic patients without HE and healthy subjects and that it was significantly higher in cirrhotic patients with HE than in the two other groups of subjects, meaning that the patients with HE had a lower body clearance than the two other groups of subjects. Taken together with the above analysis of the time course of the 13N-ammonia fractions, the data strongly indicate that metabolic conversion of ammonia is reduced in patients with de-compensated cirrhosis (here HE).
Fig. 5
Time-courses of blood concentrations of total 13N-radioactivity concentrations (black) and of 13N-ammonia (red) and 13N-metabolites (blue and black) after intravenous injection of 500 MBq 13N-ammonia tracer to a cirrhotic patient with HE (upper graph) and a healthy subject (lower graph). The time-courses of 13N-urea and 13N-glutamine are coincident in the healthy subject
Fig. 6
Area under the curves (AUC) of blood concentrations of 13N-ammonia in the groups of patients indicated (adapted from Sørensen and Keiding 2006). Since the same dose of 13N-ammonia tracer was given to all subjects (500 MBq), the AUCs reflect “inverse” whole-body ammonia clearance estimates. Data are given as mean ± standard error of the mean
×
×
The finding of a lower body clearance of ammonia cirrhotic patients with HE than cirrhotic patients without HE again underline the connection between blood ammonia and HE (Keiding et al. 2006; Iversen et al. 2009), especially because the uptake of ammonia into the brain is linearly correlated to the blood concentration of ammonia (Lockwood et al. 1979; Keiding et al. 2006).
Cerebral 13N-ammonia kinetics and blood-brain-barrier for ammonia
It has been argued that the initial brain ammonia PET kinetics can be analyzed adequately using total blood 13N-concentrations without correction for 13N-metabolites (Ahl et al. 2004). We tested this assumption by comparing the initial unidirectional clearance (K1) using 13N-ammonia concentration and total 13N-concentration as input function, respectively, in a kinetic analysis according to the diagram of the metabolic processes shown in Fig. 7 (Sørensen and Keiding 2006). As illustrated in Fig. 8, there was a slight tendency for higher K1 estimates using whole-blood 13N-concentration than 13N-ammonia concentrations at low K1 values, whereas the opposite was the case for high values of K1. However, the difference from unity was not significant, and similarly there were no significant differences between healthy subjects and the two groups of patients with cirrhosis. Hence it is acceptable to use whole-blood 13N-concentrations as input function for assessment of initial brain ammonia kinetics, including estimates of the blood-brain-barrier permeability for ammonia. In this connection it must be emphasized however, that the use of total 13N-concentration as input function for calculation of parameters for metabolic processes during quasi steady-state such as for example the net metabolic clearance (Kmet, Fig. 7) inevitably will yield incorrect results (Sørensen and Keiding 2006; Bass et al. 2009). The finding of a significant back-flux of 13N-ammonia from brain to blood (Fig. 7) as quantified by Kmet < K1 in each of the subjects from Keiding et al. (2006) (Sørensen et al. 2009) would not have been possible without using 13N-ammonia concentrations as input functions in the kinetic analyses.
Fig. 7
Simplified diagram of ammonia metabolism in brain: K1 is the unidirectional clearance of 13N-ammonia from blood into cells (ml blood/min/ml tissue), Kmet is the net metabolic clearance of 13N-ammonia from blood into intracellular of 13N-metabolites (ml blood/min/ml tissue), k2 the rate constant for back-flux from cell to blood of un-metabolized 13N-ammonia (min-1), and k3 the rate constant for conversion of 13N-ammonia to 13N-metabolites (min-1)
Fig. 8
Plot of the unidirectional clearance K1 calculated from the model shown in Fig. 7, using either whole-blood 13N-concentration (Y-axis) or 13N-ammonia concentration (X-axis) as input function using the individual PET-data from the groups of patients indicated (adapted from Sørensen and Keiding 2006)
×
×
Anzeige
Conclusion
Our fractionation of 13N-content in blood is based on modification and duplication of the original sequential solid phase extraction procedure proposed by Rosenspire et al. (1990). Recent PET-studies of brain ammonia kinetics, using this procedure (Keiding et al. 2006) underline the importance of using 13N-metabolite-corrected blood input curves for assessment of organ ammonia metabolism. The modified procedure thus enables analysis of enough blood samples to perform detailed kinetic analysis of dynamic 13N-ammonia PET studies including steady-state ammonia metabolism in brain and liver.
The present analysis of the time courses of the 13N-ammonia and 13N-metabolite curves furthermore indicate that the metabolic conversion of ammonia took place in the order: healthy subjects > cirrhotic patients without HE > cirrhotic patients with HE.
Acknowledgements
The study was supported by grants from the Novo Nordisk Foundation, the Danish Medical Research Council (271-08-0505), and the NIH (Grant 1 R01 DK074419-01).
Open Access
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Open AccessThis is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Mit e.Med Neurologie & Psychiatrie erhalten Sie Zugang zu CME-Fortbildungen der Fachgebiete, den Premium-Inhalten der dazugehörigen Fachzeitschriften, inklusive einer gedruckten Zeitschrift Ihrer Wahl.
Mit e.Med Neurologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes, den Premium-Inhalten der neurologischen Fachzeitschriften, inklusive einer gedruckten Neurologie-Zeitschrift Ihrer Wahl.
Mit e.Med Psychiatrie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Psychiatrie, den Premium-Inhalten der psychiatrischen Fachzeitschriften, inklusive einer gedruckten Zeitschrift Ihrer Wahl.
Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.
Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.
Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.
Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.
Update Neurologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
